Oncusp Therapeutics Raises Oversubscribed $100 Million Series A Financing To Advance Portfolio Of Assets For Cancer Patients
Amount Raised
$100 Million
Round Type
Series A
New YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced an oversubscribed $100 million Series A financing round.
Quick answer
OnCusp Therapeutics raised $100 Million in a Series A round, dated January 4, 2024. Investors: Bio Track Capital, Cjnv Bio Venture, Blackbird Bio Ventures, Forge Life Science Partners, Marshall Wace, Catalio Capital Management, Sofinnova Investments and F Prime Capital. OnCusp Therapeutics is based in New York, New York, United States.
- How much did OnCusp Therapeutics raise?
- OnCusp Therapeutics raised $100 Million in a Series A round on January 4, 2024.
- Who invested in OnCusp Therapeutics?
- Bio Track Capital, Cjnv Bio Venture, Blackbird Bio Ventures, Forge Life Science Partners, Marshall Wace, Catalio Capital Management, Sofinnova Investments and F Prime Capital are named as investors in this round.
- What does OnCusp Therapeutics do?
- OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments that deliver help and hope to cancer patients worldwide.
- Where is OnCusp Therapeutics based and how big is it?
- OnCusp Therapeutics is based in New York, New York, United States. Fundz records about 23 employees.
- Who are the decision-makers at OnCusp Therapeutics?
- Fundz holds 1 contact at OnCusp Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as OnCusp Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $700K on December 8, 2023.
- AIM ImmunoTech raised $3.3M (Seed) on February 16, 2024.
- Sudo Biosciences raised $147M (Series B) on February 13, 2024.
- Attralus raised $56M (Funding Round) on February 7, 2024.
- Adipo Therapeutics raised $1.9M (Seed) on January 31, 2024.
- Enterprise Therapeutics Ltd raised $33M (Series B) on January 30, 2024.
Who to call at OnCusp Therapeutics, and when
A new round usually means OnCusp Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day OnCusp Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at OnCusp Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at OnCusp Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment OnCusp Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansOnCusp Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.